Objective: Establishing an accurate histologic diagnosis is essential for determining the appropriate course of therapy for ovarian cancer. This study sought to investigate and describe nonovarian cancer pathologies discovered during the systematic laparoscopic workup of presumed advanced ovarian cancer. Methods: A retrospective cohort of patients with presumed advanced ovarian cancer (based on elevated CA125 and/or imaging) presenting to our center without confirmed pathologic diagnosis were identified and characterized. Patients without ovarian cancer on final pathology were described and compared with those with confirmed epithelial ovarian cancer using standard statistical methods. Results: Nonovarian cancer was found in 26 (7.1%) of 365 cases over 3.5 years of study, and included benign ovarian pathology, and metastatic uterine, breast, and gastrointestinal cancers. Most nonovarian cancer cases could not be diagnosed with percutaneous biopsy, and instead used diagnostic laparoscopy or assessment at the time of laparotomy for diagnosis (58%). No patient received inappropriate treatment. Nonovarian cancer cases were more likely to be nonwhite (P = 0.003), have a better Eastern Cooperative Oncology Group performance status (P G 0.001), and have a lower CA125 value (P G 0.001), and were less likely to have pleural effusions (P = 0.04). Conclusions: A systematic laparoscopic triage approach to advanced-stage ovarian cancer eliminates incorrect neoadjuvant chemotherapy administration and inappropriate laparotomy. This algorithm identified a population of women who are more likely to have nonovarian cancer pathology. Increasing screening efforts should be focused on conclusive diagnosis with the least invasive testing possible.
O varian cancer remains the eighth leading cause of death among cancers. 1 It lacks a reliable screening test and often eludes detection causing most women with ovarian, fallopian tube, and primary peritoneal cancer (grouped here as ovarian cancer) to present at advanced stages (IIIYIV), with diffuse peritoneal carcinomatosis and ascites on imaging, and/or an elevated CA125, before a definitive diagnosis. 2 These symptoms of metastatic disease may represent a primary ovarian malignancy, or other metastatic nonovarian malignancies such as breast, gastrointestinal, or uterine cancers. 3 Therefore, the National Comprehensive Care Network guidelines clearly indicate the importance of referral to a gynecologic oncologist and a requirement to obtain a histopathologic diagnosis before the consideration of a definitive treatment plan, such as neoadjuvant chemotherapy or primary debulking surgery. 4 This is essential because either of these 2 treatments for nonovarian malignancies may lead to inappropriate chemotherapies or nonindicated surgeries that compromise the delivery of quality care for the patient.
In 2013, the University of Texas MD Anderson adopted a triage algorithm to maximize patients who have no gross residual disease after primary debulking surgery, as women with microscopic residual disease have been shown to have superior survival. 5 In this algorithm, 6 patients present with presumed advanced-stage ovarian malignancy by clinical evaluation and imaging. Biopsy or fine-needle aspiration (FNA) of extraovarian metastases or cytology of peritoneal fluid obtained via paracentesis is performed for histopathologic diagnosis when indicated. Patients who are deemed surgical candidates and do not have obvious signs of extraperitoneal disease by imaging proceed to laparoscopy where assessment of the predictive index value is performed by grading the presence of tumor at 6 key sites, assigning 2 points for the presence of tumor at each site. After full workup including staging laparoscopy and confirmation of ovarian malignancy, the assessed predictive index value is then used to decide on neoadjuvant chemotherapy versus upfront debulking surgery, assigning patients to a primary debulking when their assigned laparoscopy score was less than 8, which has been shown to maximize optimal debulking rates. 7 This laparoscopic assessment also provides an additional diagnostic opportunity before laparotomy in patients without confirmed histopathologic diagnosis.
The rate of nonovarian pathology in a clinically assembled cohort of presumed advanced-stage ovarian cancer presenting to a gynecologic oncologist has not been well defined. 8Y10 This retrospective cohort study sought to identify women with unconfirmed but presumed advanced-stage ovarian malignancy presenting to a tertiary care center implementing a systematic laparoscopy-based assessment, to outline their clinical course, and to identify demographic and clinical covariates that may distinguish patients with an ovarian malignancy versus other pathology that my include benign disease or other nonovarian pathology.
MATERIALS AND METHODS
This study was approved by the University of Texas MD Anderson institutional review board. Between January 2013 and Nov 2016, we identified all adult (918 years) women who presented to our center with presumed advanced-stage ovarian malignancy based on imaging findings of an ovarian mass or carcinomatosis, and/or an elevated CA125. Patients were excluded if they had a prior histopathologic diagnosis or surgery, or were censored before obtaining a histopathologic diagnosis due to death, transfer of care, or loss to follow-up. This defined a cohort of women with unconfirmed, presumed advanced-stage ovarian malignancy undergoing our laparoscopybased triage system. Data were entered in a clinical database maintained in RedCap 11 by a clinical data coordinator. Baseline demographic and clinical criteria were recorded and included the Charlson Comorbidity Index 12 and Eastern Cooperative Oncology Group (ECOG) score, 13 among others. A gynecologic oncologist seeking to administer neoadjuvant chemotherapy or perform a primary debulking must determine the first binary questionVwhether the patient has an ovarian malignancy or not. Therefore, women were then separated into those with an ovarian malignancy on final debulking surgical specimen and those without an ovarian malignancy. When final surgical specimen was not available because surgery was not performed, the latest biopsy was used for final diagnosis. Centralized University of Texas MD Anderson gynecologic pathologists read all specimens. Diagnostic methods and final histopathologic diagnosis were reported. If patients underwent multiple or concurrent procedures (ie, core biopsy and a videoassisted thorascopic surgery), both of these procedures were reported if they yielded conclusive results. Biopsies or final specimen at laparotomy, though, were reported separately if this was the only conclusive diagnosis. Ovarian, fallopian tube, and primary peritoneal and abdominal Müllerian adenocarcinoma of unclear origin were all classified as an ovarian malignancy, whereas benign ovarian disease and nonovarian metastatic malignancies were grouped together in a ''nonovarian cancer'' group. Appropriate parametric and nonparametric tests of difference were used to compare demographic and clinical parameters between those who had an ovarian malignancy and those with other pathologies. A multivariable logistic regression was then performed to identify independent covariates that may predict nonovarian malignancy.
14 All statistical tests were 2-sided tests of difference with > = 0.05 and were performed in Stata version 12.1 (College Station, TX).
Assuming a 70% 8 rate of ovarian malignancy, this study required 303 women to have 80% power to detect a 20% difference of a hypothetical baseline covariate at 50% prevalence.
RESULTS
Data were recorded for 627 women with presumed advanced ovarian malignancy seen at the University of Texas MD Anderson Cancer Center for initial assessment between January 23, 2013, and November 16, 2016 (Fig. 1) . Some women (n = 50) did not receive any follow-up care because they were presenting for a second opinion or were lost to follow-up before further workup was performed. Among those women with complete diagnostic data, 212 had a histopathologic diagnosis before presentation for their first visit. A total of 365 were without a histopathologic diagnosis before their first appointment. As reported in Table 1 , these women were mostly elderly with a median age of 62 years, mostly white (85%), and of moderate health and performance status (Charlson comorbidity index median, 3; ECOG median performance status 1). Most (59%) had ascites on imaging and 29% had pleural effusions (Table 1) . One hundred forty-four women proceeded to laparotomy without diagnostic laparoscopy. Most women underwent a diagnostic laparoscopy to confirm the histopathologic diagnosis (44%; Fig. 1 ), whereas laparotomy was the next most common (29%) method of obtaining a final histopathologic diagnosis. These laparotomies were performed after a diagnostic laparoscopy where an incisional biopsy of the ovarian mass was avoided in lieu of resecting the primary ovarian mass intact via laparotomy, and an extraovarian mass was not present for biopsy. Most (12/15) had cases of benign disease, with the remaining 3 having a biopsy-negative metastatic breast cancer, a uterine clear cell carcinoma with concomitant dilation and curettage performed, and a uterine carcinosarcoma without uterine abnormality on computed tomographic imaging. No women received neoadjuvant chemotherapy before confirmed tissue-based diagnosis.
Most women (93%) indeed had advanced-stage ovarian cancer, most commonly serous histology (79%), with the remaining reported in Table 2 . There were 26 cases (7%) of pathology other than ovarian cancer. Half had benign disease, mostly ovarian and adnexal cysts and 1 case of endometriosis ( Table 2 ). The remaining half were nonovarian cancers metastatic to the ovary and peritoneum. Among nonovarian primary malignancies, most were of a gastrointestinal origin and included appendiceal mucinous subtypes (n = 3), pancreatic origin (n = 2), and 1 small intestinal adenocarcinoma primary. Other metastatic malignancies included uterine (1 with clear cell and 2 with carcinosarcoma) and breast cancers (n = 2), 1 peritoneal mesothelioma, and 1 B-cell lymphoma. Nonovarian cases were less likely to be diagnosed with a core biopsy (P = 0.02) or FNA (P = 0.05) performed by an interventional radiologist, and more likely to be diagnosed at laparotomy (P = 0.001). Benign cases were the most likely (92%) to be conclusively diagnosed at laparotomy versus ovarian malignancy (27%) and other malignancies (23%). Among the 159 women who underwent laparoscopy, 10 did not have an ovarian malignancy. Among the 107 who underwent laparotomy only, 15 did not have ovarian cancer. This calculates to pathologies other than ovarian cancer detected in 6.3% in the diagnostic laparoscopy algorithm versus 14.0% in those who proceeded directly to laparotomy, suggesting a number needed to treat with laparotomy of 13.7 to avoid futile laparotomy. FIGURE 1. Cohort generation. The diagram demonstrates the application of exclusion criteria to arrive at the final cohort of women with unconfirmed advanced ovarian cancer. When reporting the diagnostic details, note that some patients underwent multiple procedures, so totals reported here add to greater than the group sum.
Race was statistically significant between groups (P G 0.001), with nonwhites more likely to have other pathologies (P = 0.003). Patients ultimately diagnosed as having benign disease or other metastatic cancers had a better ECOG performance status (P G 0.001), had a lower CA125 (P G 0.001), and were less likely to have pleural effusions (P = 0.04), though a similar proportion of ascites (P = 0.80). Median CA125 was lowest in the benign group (75 mg/dL) when compared with ovarian cancer (520.7 mg/dL) and other malignancies (272.5 mg/dL) and were statistically significant in pairwise comparisons. In a multivariable regression, CA125, race, and ECOG performance status remained as independent, statistically significant predictors of ovarian malignancy versus other pathology. In a second multivariable regression to predict other primary cancers metastatic to the ovary, race and performance status were predictive at a statistically significant level. 
DISCUSSION
This study demonstrated that cases of presumed advanced ovarian cancer are successfully diagnosed with a laparoscopicbased algorithm to avoid inappropriate treatment, and also identified a population of women more likely to have diagnoses other than ovarian malignancy. Core biopsy, cytology, and FNA were successful in a minority of cases, but diagnostic laparoscopy was successful in arriving at a final histopathologic diagnosis in most cases. Laparotomy was more common in the nonovarian cancer cohort, although most of these patients had benign diseases that were unable to be conclusively diagnosed without full surgical resection because of size of the ovarian mass or lack of other lesions for biopsy targets. The remaining metastatic nonovarian primaries had a workup that included biopsies of any target lesion and colonoscopies when indicated. These patients with metastatic nonovarian primary malignancies presented with pelvic masses or peritoneal carcinomatosis on imaging; those with other easily identifiable disease sites were unlikely to first present to a gynecologic oncologist and would not be present in this cohort. This difficult population, though rare, unfortunately required full surgical resection for conclusive diagnosis.
The diagnostic utility of imaging 8 and biopsy by FNA, 9 image-guided core biopsy, 10 and video-assisted thoracoscopic surgery 15 have been described elsewhere, but have not been reported together in a full cohort of women with unconfirmed, presumed advanced-stage ovarian malignancy managed with a systematic triage system. These prior studies investigating the diagnostic course of women presenting with unconfirmed presumed ovarian malignancy found rates of ovarian malignancy at 64%, 8 41%, 9 and 74%. 10 This study's rate of confirmed ovarian malignancy (93%) is much higher than these other assembled cohorts of women with presumed advancedstage ovarian cancer. Our study was performed at a tertiary/ quaternary-level cancer center, where patients often have a histopathologic diagnosis before their first visit with an oncologist and thus enrich the population for true ovarian cancer cases. In addition, imaging has improved since these prior studies (some as early as 1999) and has likely led to improved diagnosis and triage to the correct oncologic surgeon or general gynecologist. This cancer center population may not be fully generalizable because 50 patients followed up in other centers, but the utility of diagnostic laparoscopy applies to all patients with suspected advanced-stage ovarian cancer who are candidates for a surgical procedure, and the risk factors for nonovarian cancer would likely apply to other gynecologic oncology practices.
This study demonstrates that women with pathologies other than ovarian cancer can be successfully diagnosed with a systematic diagnostic laparoscopy-based system when feasible, to follow National Comprehensive Care Network guidelines. This is an important benefit in addition to the utility of diagnostic laparoscopy in triaging patients to neoadjuvant chemotherapy versus primary debulking to maximize surgeries without residual disease. This study identifies a population of women who likely do not have advanced ovarian cancerVthose with a lower CA125 level, of nonwhite race, and better performance status. This study can thus help guide the workup leading to a diagnostic laparoscopy before laparotomy. The benefits of this diagnostic laparoscopyVavoiding a futile laparotomy and preventing inappropriate neoadjuvant chemotherapy administrationVvastly outweigh the negatives of a $350 reimbursement, 16 additional minimally invasive procedure, and 1-week delay in laparotomy, if indicated. This study was not powered to develop and test a predictive model. The study findings could help practitioners direct resources to these patients, including aggressively screening for the metastatic primaries identified in this study. These modalities are mostly minimally invasive procedures (ie, endometrial biopsy for uterine malignancy, endoscopy for gastrointestinal malignancy, and mammograms for breast cancer) and should therefore be performed when indicated before more invasive surgeries.
